1
|
Zhang N, Liu C, Di W. Systemic Treatment for Gynecological Cancer Patients Undergoing Hemodialysis. Onco Targets Ther 2023; 16:545-558. [PMID: 37448551 PMCID: PMC10337679 DOI: 10.2147/ott.s419445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2023] [Accepted: 07/01/2023] [Indexed: 07/15/2023] Open
Abstract
Gynecological cancer poses a serious threat to women's health. Chemotherapy-based systemic therapy plays a crucial role in the treatment of gynecological cancers. Many systemic therapeutic drugs are metabolized in the kidneys. Therefore, normal renal function is a prerequisite for gynecological tumor patients to complete the full course of systematic treatment and provide a guarantee for achieving an ideal prognosis. Chronic kidney disease often places restrictions on systematic treatment to different extents, such as influencing drug pharmacokinetics, increasing drug toxicity, and the risk of adverse drug reactions. Unfortunately, women undergoing renal replacement have a higher risk of developing gynecological cancers. This article summarizes the current knowledge on systemic treatment drugs for patients with gynecological cancer undergoing dialysis. We discuss the optimal choice of the systematic therapeutic protocol, administration of form and dosage, and window of chemotherapy during hemodialysis sessions to ensure both effectiveness and safety in gynecological cancer patients.
Collapse
Affiliation(s)
- Nan Zhang
- Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
- Shanghai Key Laboratory of Gynecologic Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
| | - Chang Liu
- Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
- Shanghai Key Laboratory of Gynecologic Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
- Center for Reproductive Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
| | - Wen Di
- Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
- Shanghai Key Laboratory of Gynecologic Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
- State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
| |
Collapse
|
2
|
Anai S, Ibusuki R, Takao T, Sakurai Y, Hisasue J, Takaki Y, Hara N. Retrospective cohort study on the safety and efficacy of docetaxel in Japanese non-small cell lung cancer patients with nondialysis chronic kidney disease stage 3b or higher. Thorac Cancer 2019; 10:2282-2288. [PMID: 31631526 PMCID: PMC6885428 DOI: 10.1111/1759-7714.13222] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 09/26/2019] [Accepted: 09/26/2019] [Indexed: 11/28/2022] Open
Abstract
Background It has been reported that 20% of lung cancer patients have renal impairment caused by chronic kidney disease (CKD). Since docetaxel is predominantly excreted by the hepatobiliary system, it is administered to non‐small cell lung cancer (NSCLC) patients with renal impairment. However, few clinical data are available on the toxicity and efficacy of docetaxel for patients with nondialysis renal impairment. Furthermore, some cases of tubular nephrotoxicity caused by docetaxel in NSCLC patients have been reported. Therefore, a retrospective cohort study was conducted to assess the influence of nondialysis CKD on the toxicity and efficacy of docetaxel in NSCLC patients. Methods NSCLC patients who received docetaxel were assessed for renal function, occurrence of adverse events and treatment efficacy. Results A total of 34 NSCLC patients who received docetaxel were studied. Eight (23.5%) patients had nondialysis CKD stage 3b or higher, with an estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2. Although the differences were not statistically significant, the starting dose of docetaxel (mg/m2) was lower (60 mg/m2; 37.5% vs. 69.2%) in patients with an eGFR <45 than that in patients with an eGFR ≥45. No significant association was observed between pretreatment eGFR and hematological and nonhematological toxicities. No significant difference was observed in the disease control rate (62.5% vs. 65.4%, P = 1.000) or in the median overall survival (10.7 vs. 11.7, P = 0.735) between patients with an eGFR <45 and those with an eGFR ≥45. Conclusion Docetaxel is a reasonable option for NSCLC patients with nondialysis CKD stage 3b or higher. Dose reduction of docetaxel is also a possibility for NSCLC patients with CKD stage 3b or higher.
Collapse
Affiliation(s)
- Satoshi Anai
- Department of Respiratory Medicine, Harasanshin Hospital, Fukuoka, Japan
| | - Ritsu Ibusuki
- Department of Respiratory Medicine, Harasanshin Hospital, Fukuoka, Japan
| | - Tomoaki Takao
- Department of Respiratory Medicine, Harasanshin Hospital, Fukuoka, Japan
| | - Yuko Sakurai
- Department of Respiratory Medicine, Harasanshin Hospital, Fukuoka, Japan
| | - Junko Hisasue
- Department of Respiratory Medicine, Harasanshin Hospital, Fukuoka, Japan
| | - Yoichi Takaki
- Department of Respiratory Medicine, Harasanshin Hospital, Fukuoka, Japan
| | - Naohiko Hara
- Department of Respiratory Medicine, Harasanshin Hospital, Fukuoka, Japan
| |
Collapse
|
3
|
Simões J, Augusto I, Meireles S, Vendeira L, Silva C. Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis. AUTOPSY AND CASE REPORTS 2018; 8:e2018011. [PMID: 29780751 PMCID: PMC5953181 DOI: 10.4322/acr.2018.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2017] [Accepted: 02/09/2018] [Indexed: 11/23/2022] Open
Abstract
At a time when the population shows increasing longevity, entities such as cancer and chronic
kidney disease (CKD) are more frequently connected. In the United States, approximately
6% of the patients on hemodialysis have cancer. The challenge to manage oncologic patients
with CKD in a hemodialytic program represents a great shortage of available information on
the choice of the best drug, timing, dosage adjustments, dialysis method, and treatment safety.
We present the case of a patient with prostate cancer and terminal CKD in hemodialysis, and
the treatment sequence after the development of resistance to hormonal blockade therapy,
which included docetaxel, enzalutamide, and radium-223.
Collapse
Affiliation(s)
- Joana Simões
- University of Porto, Centro Hospitalar de São João, Department of Oncology . Porto , Portugal
| | - Isabel Augusto
- University of Porto, Centro Hospitalar de São João, Department of Oncology . Porto , Portugal
| | - Sara Meireles
- University of Porto, Centro Hospitalar de São João, Department of Oncology . Porto , Portugal
| | - Lurdes Vendeira
- University of Porto, Centro Hospitalar de São João, Department of Urology . Porto , Portugal
| | - Carlos Silva
- University of Porto, Centro Hospitalar de São João, Department of Radiation Oncology . Porto , Portugal
| |
Collapse
|
4
|
Pedrazzoli P, Silvestris N, Santoro A, Secondino S, Brunetti O, Longo V, Mancini E, Mariucci S, Rampino T, Delfanti S, Brugnatelli S, Cinieri S. Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). ESMO Open 2017; 2:e000167. [PMID: 29209521 PMCID: PMC5703391 DOI: 10.1136/esmoopen-2017-000167] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Revised: 04/30/2017] [Accepted: 05/02/2017] [Indexed: 12/31/2022] Open
Abstract
Background The overall risk of some cancers is increased in patients receiving regular dialysis treatment due to chronic oxidative stress, a weakened immune system and enhanced genomic damage. These patients could benefit from the same antineoplastic treatment delivered to patients with normal renal function, but a better risk/benefit ratio could be achieved by establishing specific guidelines. Key considerations are which chemotherapeutic agent to use, adjustment of dosages and timing of dialysis in relation to the administration of chemotherapy. Methods We have reviewed available data present in the literature, including recommendations and expert opinions on cancer risk and use of chemotherapeutic agents in patients with end-stage renal disease. Experts selected by the boards of the societies provided additional information which helped greatly in clarifying some issues on which clear-cut information was missing or available data were conflicting. Results Data on the optimal use of chemotherapeutic agents or on credible schemes of polychemotherapy in haemodialysed patients are sparse and mainly derive from case reports or small case series. However, recommendations on dosing and timing of dialysis can be proposed for the most prescribed chemotherapeutic agents. Discussion The use of chemotherapeutic agents as single agents, or in combination, can be safely given in patients with end-stage renal disease. Appropriate dosage adjustments should be considered based on drug dialysability and pharmacokinetics. Coordinated care between oncologists, nephrologists and pharmacists is of pivotal importance to optimise drug delivery and timing of dialysis.
Collapse
Affiliation(s)
- Paolo Pedrazzoli
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Nicola Silvestris
- Department of Medical Oncology, Cancer Institute "Giovanni Paolo II", Bari, Italy
| | - Antonio Santoro
- Division of Nephrology, Dialysis and Hypertension, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - Simona Secondino
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Oronzo Brunetti
- Department of Medical Oncology, Cancer Institute "Giovanni Paolo II", Bari, Italy
| | - Vito Longo
- Medical Oncology Unit, Ospedale di Taranto, Taranto, Italy
| | - Elena Mancini
- Division of Nephrology, Dialysis and Hypertension, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - Sara Mariucci
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Teresa Rampino
- Nephrology, Dialysis and Transplantation Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Sara Delfanti
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Silvia Brugnatelli
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Saverio Cinieri
- Department of Medical Oncology and Breast Unit, Sen. Antonio Perrino Hospital, Brindisi, Italy
| |
Collapse
|
5
|
Yang L, Zhang XC, Yu SF, Zhu HQ, Hu AP, Chen J, Shen P. Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report. BMC Cancer 2015; 15:917. [PMID: 26582454 PMCID: PMC4652348 DOI: 10.1186/s12885-015-1932-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2014] [Accepted: 11/13/2015] [Indexed: 11/22/2022] Open
Abstract
Background Standardized chemotherapy used in cancer patients with severe kidney insufficiency is ineffective. Although there are some pharmacokinetic studies on cyclophosphamide in kidney insufficiency patients, to the best of our knowledge, the pharmacokinetics and safety of combination of cyclophosphamide and docetaxel as postoperative chemotherapy in a patient with early stage breast cancer undergoing hemodialysis is unclear thus far. Case Presentation The patient received regular TC regimen (cyclophosphamide 600 mg/m2, docetaxel 75 mg/m2). She underwent hemodialysis 48 h after chemotherapy. Blood samples at multiple time-points were collected for determination of plasma levels of cyclophosphamide and docetaxel. Pharmacokinetic analyses indicated that compared with the reference data, the in vivo half-life (66.96 h) and drug exposure (150 %) of cyclophosphamide significantly increased; however, pharmacokinetic parameters of docetaxel was unaffected. Patient developed grade I thrombocytopenia and grade III leukopenia without any other severe adverse reactions. In total, four cycles of treatment were completed. After the chemotherapy, the patient received tamoxifen as endocrine therapy for one and a half years. No recurrence was reported. Conclusion These results suggest that the standard TC regimen is mostly safe and could be used as postoperative adjuvant chemotherapy for hemodialysis patients with early stage breast cancer.
Collapse
Affiliation(s)
- Liu Yang
- Department of Medical oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79#, Hangzhou, Zhejiang, 310003, People's Republic of China. .,Department of Medical Oncology, Zhejiang Provincial People's Hospital, Hangzhou, 310014, People's Republic of China.
| | - Xiao-chen Zhang
- Department of Medical oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79#, Hangzhou, Zhejiang, 310003, People's Republic of China.
| | - Su-feng Yu
- Department of Medical oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79#, Hangzhou, Zhejiang, 310003, People's Republic of China.
| | - Hua-Qing Zhu
- Department of Medical oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79#, Hangzhou, Zhejiang, 310003, People's Republic of China.
| | - Ai-ping Hu
- Department of Medical oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79#, Hangzhou, Zhejiang, 310003, People's Republic of China.
| | - Jian Chen
- Department of Pharmacy, the First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79#, Hangzhou, Zhejiang, 310003, People's Republic of China.
| | - Peng Shen
- Department of Medical oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79#, Hangzhou, Zhejiang, 310003, People's Republic of China.
| |
Collapse
|
6
|
Takimoto T, Nakabori T, Osa A, Morita S, Terada H, Oseto S, Iwazawa T, Abe K. Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients. Int J Clin Oncol 2011; 17:395-8. [PMID: 21853293 DOI: 10.1007/s10147-011-0304-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2011] [Accepted: 07/29/2011] [Indexed: 11/28/2022]
Abstract
Renal dysfunction is a characteristic of many patients with cancer; however, a standard therapy has not been established for stage III or IV non-small-cell lung cancer (NSCLC) complicated with chronic renal failure. Docetaxel has a proven significant activity against NSCLC. This agent is predominantly eliminated by hepatobiliary extraction and is safe in patients with renal failure, including dialysis patients. Docetaxel is, thus, a therapeutic option in that patient population. Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. Little is known about tubular nephrotoxicity induced by docetaxel; however, oncologists should be aware of its possibility.
Collapse
Affiliation(s)
- Takayuki Takimoto
- Department of Internal Medicine, Toyonaka Municipal Hospital, 4-14-1 Shibahara-cho, Toyonaka, Osaka, 560-8565, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010; 21:1395-1403. [PMID: 20118214 DOI: 10.1093/annonc/mdp598] [Citation(s) in RCA: 107] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND The increased incidence of malignancies in patients with chronic renal failure has been discussed since the mid-70s. On the other hand, the high frequency of chronic renal insufficiency among cancer patients has been recently assessed in the Insuffisance Rénale et Médicaments Anticancéreux Study which demonstrated a prevalence as high as 50%-60% of the patients for all stages of kidney disease. Furthermore, the incidence of end-stage renal disease is growing worldwide and so is the number of patients on chronic dialysis, hemodialysis (HD) for the large majority of them. As a result, the question of cytotoxic drug handling in those patients in terms of dosage adjustment and time of administration regarding the dialysis sessions needs to be addressed to optimize cytotoxic drug therapy in those patients. METHODS We reviewed the international literature on the pharmacokinetics, efficacy, tolerance and dosage adjustment of cytotoxic drugs used to treat solid tumor patients and when available, specific literature on HD cancer patients. RESULTS From these data, dosing recommendations are given for the most prescribed cytotoxic drugs in clinical practice. CONCLUSIONS Dosage adjustments are often necessary in HD cancer patients. These adaptations have to be carefully carried out to optimize drug exposure, ensure efficacy and reduce the risk of side-effects.
Collapse
Affiliation(s)
- N Janus
- ICAR-Department of Nephrology, Pitié-Salpêtrière Hospital, Paris.
| | - J Thariat
- Department of Radiation Oncology, Centre Antoine Lacassagne, University of Nice Sophia-Antipolis, Nice
| | - H Boulanger
- Department of Nephrology and Dialysis, Clinique de l'Estrée, Stains, France
| | - G Deray
- ICAR-Department of Nephrology, Pitié-Salpêtrière Hospital, Paris
| | - V Launay-Vacher
- ICAR-Department of Nephrology, Pitié-Salpêtrière Hospital, Paris
| |
Collapse
|
8
|
Strother RM, Sweeney C. Lessons learned from development of docetaxel. Expert Opin Drug Metab Toxicol 2008; 4:1007-19. [DOI: 10.1517/17425255.4.7.1007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
9
|
Hilbe W, Aigner K, Dittrich C, Eckmayr J, Fiegl M, Flicker M, Forstner B, Greil R, Jamnig H, Krajnik G, Lang A, Mohn-Staudner A, Schinko H, Studnicka M, Pirker R, Ploner F, Rothmund J, Schiller L, Zabernigg A, Zöchbauer-Müller S. Expertenempfehlung 2006 zur rationalen Zweitlinien-Therapie beim nicht-kleinzelligen Bronchuskarzinom. Wien Klin Wochenschr 2007; 119:259-66. [PMID: 17492355 DOI: 10.1007/s00508-007-0792-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- Wolfgang Hilbe
- Medizinische Universität Innsbruck, Klinische Abteilung für Allgemeine Innere Medizin, Schwerpunkt Onkologie, Innsbruck, Austria.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|